Lead Programs

MRSA Decolonization

Onychomycosis (Nail Fungus)

Nasal Decolonization

Nasal Decolonization is a common part of pre-operative protocols to reduce the likelihood of surgical site infections caused by MRSA.

Standard of Care (Bactroban Nasal) was discontinued in 2020.

Our ointment formulation employs an identical delivery format and is:


Effective against MRSA and several other nosocomial pathogens


Non-irritating, non-sensitizing, non-cytotoxic, and biocompatible with mucosa


Polyhexanide is a new chemical entity that has shown no signs of resistance in 75+ years of use


Program meets eligibility requirements for FDA’s QIDP program (21 CFR 317.2)

(Nail Fungus)

Onychomycosis is an infection of the nail that causes discoloration, thickening, and separation from the nail bed. It occurs in*:

0 %
Of the general population
0 %
Of persons older than 60
0 %
Of those older than 70

Preliminary research conducted by key opinion leading physician suggests our flagship formula’s potential efficacy is ~70-85% (n=100) for the treatment of Onychomycosis.

Topical Antifungals are widely considered ineffective per CDC** (6-16%), yet still generate billions of dollars in revenue annually.

Turn Therapeutics Reaches Licensing and Distribution Agreement with MIMEDX